New drug duo targets Hard-to-Treat lung cancer

NCT ID NCT07264816

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced non-squamous non-small cell lung cancer that has high levels of a protein called HER2. The goal is to see if the combination shrinks tumors and how safe it is. About 80 adults aged 18 to 75 are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a drug given by IV) and pembrolizumab (an immunotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has HER2 overexpression.
What could go wrong: This is an early Phase II trial with only 80 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.